Deals Of The Week: Merck KGaA/Ono, Puma/Pfizer, AstraZeneca /MedImmune/Pfizer…
Executive Summary
Each week, “The Pink Sheet” presents commentary on some of the week’s most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at http://invivoblog.blogspot.com.
You may also be interested in...
In Private Equity Hands, PPD Could Seek More Deals
Two private equity firms’ agreement to acquire Pharmaceutical Product Development Inc. and take the company private is the latest and largest deal in a recent spate of PE activity among contract research organizations – and perhaps not the last, or even least.
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
AZ's Rare Disease Unit Reports Positive Phase III Results For Copper-Binding ALXN1840
Alexion/AstraZeneca has announced positive top-line results from the Phase III study of ALXN1840 in patients with the rare genetic disorder, Wilson disease, including in patients already on standard-of-care therapies. The compound is ahead of two candidate gene therapies from other companies at early-stage clinical development.